Executive Summary
Corona Remedies Ltd reported Q3FY26 revenues of ₹342 crore, up 14.37% YoY, with consolidated net profit increasing 39.13% to ₹64 crore despite higher expenses. Strong pharmaceutical demand drove topline growth while operational efficiencies supported margin expansion amid industry tailwinds.
Revenue & Growth
Revenues grew to ₹342 crore from ₹298 crore YoY, reflecting solid 15% expansion primarily from branded generics and chronic therapy portfolios. Total expenses rose 11.18% YoY to ₹507 crore, moderated relative to revenue acceleration through better supply chain management.
Profitability & Margins
Consolidated net profit surged 39.13% YoY to ₹64 crore from ₹45 crore, with EBITDA reaching ₹83 crore at impressive 24.3% margins (up 100 bps YoY). Basic EPS improved 36.84% to ₹2.08 from ₹1.52, excluding one-time labor code provisions.
Balance-Sheet Highlights
The dataset shows healthy liquidity with net working capital days at 18 and strong OCF/EBITDA conversion of 86.3% for 9MFY26. Annualized RoE at 31.1% and RoCE at 48% highlight capital efficiency in pharma operations.
Cash Flow / Liquidity
9M FY26 operating cash flow demonstrates high-quality earnings with 86.3% EBITDA conversion, supporting working capital needs and growth capex.
Key Ratios / Metrics
EBITDA margin expanded to 24.3%; PAT margin at 16.2% (adjusted). 9M revenue up 16.3% to ₹1,050 crore with PAT growth of 30.7% to ₹154 crore, positioning for sustained pharma sector momentum.